Vimarsana
Biggest News Aggregation in the World

Page 13 - Protein Sciences Segment News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Protein Sciences Segment. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Protein Sciences Segment Today - Breaking & Trending Today

Bio-Techne Releases Second Quarter Fiscal 2021 Results - Vimarsana News

Bio-Techne Releases Second Quarter Fiscal 2021 Results

Share this article Share this article MINNEAPOLIS, Feb. 2, 2021 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ:TECH) today reported its financial results for the second quarter ended December 31, 2020. Second Quarter FY2021 Snapshot Second quarter organic revenue increased by 19% (21% reported) to $224.3 million and 15% (16% reported) in the first half of fiscal 2021 to $428.5 million.   GAAP EPS was $1.15 versus $3.02 one year ago primarily relating to a non-recurring gain of approximately $121 million in our ChemoCentryx investment in the second quarter of fiscal 2020. Delivered record a...

Bio-Techne To Host Conference Call On February 2, 2021 To Announce Second Quarter 2021 Financial Results - Vimarsana News

Bio-Techne To Host Conference Call On February 2, 2021 To Announce Second Quarter 2021 Financial Results

/PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today announced that management will host a conference call and webcast on Tuesday, February 2, 2021, at...

ScaleReady Launches With the Mission to Revolutionize T Cell Therapy Manufacturing - Vimarsana News

ScaleReady Launches With the Mission to Revolutionize T Cell Therapy Manufacturing

ScaleReady Launches With the Mission to Revolutionize T Cell Therapy Manufacturing ScaleReady Launches With the Mission to Revolutionize T Cell Therapy Manufacturing ScaleReady, a joint venture between Bio-Techne (NASDAQ: TECH), Fresenius Kabi, and Wilson Wolf, launches today. The new company brings together proven tools and technologies for cell culture, cell activation, gene editing, and cell processing from its founding partners. ScaleReady provides leading therapeutic developers with the most simple, scalable, and versatile manufacturing platform in the industry, enhancing the prospect...

ScaleReady Launches With the Mission to Revolutionize T Cell Therapy Manufacturing - Vimarsana News

ScaleReady Launches With the Mission to Revolutionize T Cell Therapy Manufacturing

ScaleReady Launches With the Mission to Revolutionize T Cell Therapy Manufacturing ScaleReady is a joint venture between Bio-Techne, Fresenius Kabi, and Wilson Wolf ScaleReady's mission is to make the business of cell and gene therapy practical and viable by providing the most simple, scalable and versatile manufacturing platform in the industry ScaleReady will provide sales, marketing, and application support for customers globally ScaleReady, a joint venture between Bio-Techne (NASDAQ: TECH), Fresenius Kabi, and Wilson Wolf, launches today. The new company brings together proven tools and ...